Skip to content

Neutralizing SARS-CoV-2-specific Antibodies and Virus-Specific T Cells Detected in People Recovering from COVID-19

In This Article

  • Researchers in China completed serological assessments of 14 patients who had been hospitalized for COVID-19 and became virus-free
  • Not only were SARS-CoV-2-specific antibodies detected, but in most patients the antibodies were neutralizing—capable of protecting against re-infection
  • There was also evidence of a virus-specific T cell response
  • There was strong correlation between neutralization antibody titers and the number of virus-specific T cells, suggesting an integrated humoral and cellular immune response
  • While more research is needed, these findings are additional assurance that natural infection confers protective immunity and that future vaccination may be effective

Studies of SARS-CoV, MERS-CoV and non-SARS coronaviruses, as well as a non–peer-reviewed, pre-print study of rhesus monkeys, suggest humans should possess protective immunity to SARS-CoV-2 after infection. This research was discussed in a fast literature update posted on April 24, 2020.

The newest study of protective immunity in patients recovering from COVID-19, published in Immunity, is the most comprehensive yet. Its promising results are discussed by Tiara Calhoun, MD, Internal Medicine and Global Medicine resident, and Vladimir Vinarsky, MD, a physician in the Division of Pulmonary and Critical Care, with advisory review by Rod Rahimi, MD, PhD, all of Massachusetts General Hospital, in a fast literature update posted on May 5.

Participants and Methods

The researchers evaluated blood samples from eight patients being discharged from a university hospital in Beijing. They also examined blood samples obtained two weeks after discharge from a separate group of six patients. All patients had a positive SARS-CoV-2 nucleic acid test and radiographic signs of mild COVID-19.

SARS-CoV-2-specific Antibodies

Blood from all 14 patients showed IgM and IgG antibodies specific to two proteins derived from SARS-CoV-2: the viral nucleocapsid protein (NP) and the receptor-binding domain of the spike protein (S-RBD). These antibodies were not detected in healthy controls.

Humoral Immune Response

For S-RBD, although not NP, there was a strong correlation between antibody titer and neutralizing activity against SARS-CoV-2.

Cellular Immune Response

The number of T cells secreting interferon-gamma was higher in recovered COVID-19 patients than in controls, suggesting a SARS-CoV-2-specific T cell response. There was also a strong correlation between neutralization antibody titers and the number of virus-specific T cells.

Commentary

  • Similar to all prior COVID-19 immunology studies, a very small number of patients were evaluated
  • No information is given about changes in immunity over time in the same patients
  • It remains unknown what antibody titer or number of memory T cells is needed to confer protection

This study provides encouraging, but certainly not definitive, evidence that humans develop protective immunity after COVID-19.

View all COVID-19 updates

Learn more about immunology research at Mass General

Related topics

Related

Massachusetts General Hospital researchers believe that people will likely develop protective immunity after infection with the novel coronavirus, SARS-CoV-2, but immunity may wane over time.

Related

Massachusetts General Hospital Researchers conclude that nosocomial infection appears to be associated with increased mortality in patients with COVID-19.